Financial PerformancePreliminary revenue for the nine months ended September 30, 2024, was up approximately 98% year-over-year, showing significant growth.
Product ValidationIceCure received marketing authorization from the FDA for the next-generation XSense single probe cryoablation system, which further validates the company’s cryoablation platform technology and should help strengthen market penetration.
Regulatory ApprovalThe FDA Medical Device Advisory Committee Panel gave a favorable recommendation for ICCM's ProSense System for the treatment of early-stage low-risk invasive breast cancer, indicating a high likelihood of approval.